You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Scheduling of potassium chloride

National Drugs and Poisons Schedule Committee media release

18 October 2006

At its meeting on 10th-12th October 2006, the National Drugs and Poisons Schedule Committee (NDPSC) further considered the scheduling of potassium chloride in light of recommendations from a report from the NSW Deputy Coroner.

Over the course of four meetings, the Committee considered submissions from a broad spectrum of stakeholders and agreed at the October 2006 Meeting to amend the current wording of the Schedule 4 entry for potassium chloride.

The Committee noted that the amended entry would exclude all currently marketed glucosamine sulfate products complexed with potassium chloride.

In accordance with the Committee's practice and statutory requirements, a record of reasons for this and other scheduling decisions made at this meeting will be publicly available within the next two months.

The amended entry, which is expected to take effect through relevant State and Territory legislation in May 2007, will be as follows:

POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:

  1. when containing less than 600mg of potassium chloride per dosage unit;
  2. in preparations for oral rehydration therapy;
  3. in preparations for enteral feeding; or
  4. in preparations for bowel cleansing prior to diagnostic medical and surgical procedures.

Media contact: Kay McNiece, 02 6289 5027